SMS Co., Ltd.
Notice of Decision on Policy to Sell or Withdraw from the Medical Platform Business
Procedures have been initiated to sell or withdraw from the Medical Platform business. The counterparty, method, and timing are undecided, and the impact on consolidated results for the fiscal year ending March 2027 and beyond is under review. At this time, the full-year forecast (fiscal year ending March 2027) remains unchanged from the previously disclosed figures.
Key Figures
- Net Sales: 71,834 million yen
- Operating Income: 6,801 million yen
- Ordinary Income: 8,731 million yen
- Net Income Attributable to Owners of Parent: 6,165 million yen
AI要約
Review of Business Strategy and Decision to Pursue Sale
At the Board of Directors meeting held on October 29, 2026, it was resolved to proceed with procedures to sell or withdraw the Medical Platform business operated by the consolidated subsidiary MIMS Group to a third party. Based on the past roadmap, the aim is to maximize value under a partner with strong capital and product development capabilities and to concentrate management resources on higher capital-return businesses such as the career business and management support business. Specific details regarding counterparties, methods, and execution timing are undecided and will be promptly disclosed once determined.
Impact and Future Outlook
The impact of this sale or withdrawal on consolidated results for the fiscal year ending March 2027 and thereafter is currently being examined. Decisions and any effects on results will be disclosed in a timely manner once known. The consolidated earnings forecast for the fiscal year ending March 2027 remains unchanged from the figures announced on April 28, 2026.
SMS Co., Ltd.
Company overview · Stock price · Financial data · All IR
